New anti-parasitic drugs for a global veterinary market. This project aims to establish an advanced, industry-linked pipeline for the development of new drugs against resilient infectious agents (parasites) that cause serious diseases in billions of animals worldwide. The research expects to discover new ways of killing parasites that survive in their host animal, despite being under severe attack by the host immune system. The resultant shift in fundamental understanding will lead to innovative ....New anti-parasitic drugs for a global veterinary market. This project aims to establish an advanced, industry-linked pipeline for the development of new drugs against resilient infectious agents (parasites) that cause serious diseases in billions of animals worldwide. The research expects to discover new ways of killing parasites that survive in their host animal, despite being under severe attack by the host immune system. The resultant shift in fundamental understanding will lead to innovative technologies or products to ameliorate the burden of parasites in livestock animals. Expected socioeconomic benefits include commercial products for end-users and lifting Australia’s scientific knowledge base, reputation in biotechnology, livestock production and investment in translational research.Read moreRead less
Antiviral compounds to inhibit the replicase of hepatitis C virus. Hepatitis C virus is a major public health problem. There are currently 200,000 infected individuals in Australia and 16,000 new infections every year. There is no specific treatment and current therapy treats a small percentage of patients only, which consists of interferon-alpha and ribavirin. This results in side effects and only a 50% cure rate. This study's outcomes are expected to lead to greater access to treatment and imp ....Antiviral compounds to inhibit the replicase of hepatitis C virus. Hepatitis C virus is a major public health problem. There are currently 200,000 infected individuals in Australia and 16,000 new infections every year. There is no specific treatment and current therapy treats a small percentage of patients only, which consists of interferon-alpha and ribavirin. This results in side effects and only a 50% cure rate. This study's outcomes are expected to lead to greater access to treatment and improved therapy resulting in higher cure rates and in a dramatic reduction in the cost of treating patients. A novel therapy will provide considerable benefits for the national biotechnology industry.Read moreRead less
The dynamics of viral latency in chronic infection. Although many acute infections can now be controlled, we still suffer from a large number of chronic infections such as HIV or herpes that cannot be eradicated. Many of these infections persist because they can lie dormant in a 'latent' state. How this latent state is established, and how long it lasts are important to understand if we want to control these infections. We have assembled a team of mathematicians, immunologists and virologists in ....The dynamics of viral latency in chronic infection. Although many acute infections can now be controlled, we still suffer from a large number of chronic infections such as HIV or herpes that cannot be eradicated. Many of these infections persist because they can lie dormant in a 'latent' state. How this latent state is established, and how long it lasts are important to understand if we want to control these infections. We have assembled a team of mathematicians, immunologists and virologists in order to study latent infection at the cellular level, and within infected monkeys. This will provide the first insights into the dynamics of latency - how these cells are produced and die - and should lead to novel approaches to controlling chronic infection.Read moreRead less